Currently Viewing:
The Academy of Managed Care Pharmacy (AMCP) 2019
Trust Is the Key Ingredient in Medicaid Value-Based Contracts, Manufacturers and Payers Agree
March 26, 2019
Keeping an Eye on Increasing Competition in the Specialty Drug Pipeline
March 27, 2019
Dr Sebastian Schneeweiss on How Rapid-Cycle Analytics Can Identify High-Risk, High-Cost Patients
March 27, 2019
Dr Crescent Moore Outlines Part D Changes to Expect in 2020
March 27, 2019
The Balancing Act of Using Pharmacy Strategies to Fight the Opioid Epidemic
March 27, 2019
Current and Future Status of Drug Pricing Reform as the Blueprint Approaches the 1-Year Mark
March 27, 2019
Dr Steven Pearson: ICER Can Provide More Information When a Drug is Approved With Limited Data
March 28, 2019
Sophie Schmitz on the Importance of Considering Value of Gene Therapies, Not Just Cost
March 28, 2019
Managing Cholesterol With PCSK9 Inhibitors and Overcoming Operational Challenges in Practice
March 28, 2019
Currently Reading
Dr James Chambers Discusses Variability in Specialty Drug Coverage and Its Impact
March 29, 2019
Costs of Living With HIV Can Be Mitigated by Rapid Initiation of ART Post Diagnosis
March 29, 2019
Real-Time Prescription Benefit Checks Could Provide Accurate Cost Estimates at the Point of Prescribing
April 01, 2019
Dr Brian MacDonald Explains How Technology Can Improve Patient Management Strategies
April 10, 2019
Dr Crescent Moore on the Effect of Step Therapy in MA Plans, Other Formulary Regulations
April 13, 2019
Dr Michael Steinman on the Importance of Medication Management Strategies for Older Adults
April 15, 2019
Dr Sebastian Schneeweiss: How Payers Can Benefit From Rapid-Cycle Analytics of Real-World Evidence
April 19, 2019
Dr Crescent Moore on Implementing Care Coordination Programs in Medicare
April 25, 2019
Dr Sebastian Schneeweiss Discusses How Rapid-Cycle Analytics Can Evaluate Drug Safety, Efficacy
May 01, 2019
Dr Michael Steinman Details Opportunities for Improving Medication Management Strategies
May 05, 2019
Dr Crescent Moore Outlines CMS' Efforts to Address the Opioid Epidemic
May 13, 2019
Dr Sebastian Schneeweiss: In 5 Years, Rapid-Cycle Analytics Will Account for Majority of Analyses
May 15, 2019
Dr Jane Barlow on Innovations, Limitations Within Alternative Payment Models
January 14, 2020

Dr James Chambers Discusses Variability in Specialty Drug Coverage and Its Impact

A study found that out of hundreds of specialty drugs, only 16% were covered in the same way by 17 commercial payers in the United States, meaning that 84% of those specialty drugs had differing coverage, explained James D. Chambers, PhD, MPharm, MSc, associate professor, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center.


A study found that out of hundreds of specialty drugs, only 16% were covered in the same way by 17 commercial payers in the United States, meaning that 84% of those specialty drugs had differing coverage, explained James D. Chambers, PhD, MPharm, MSc, associate professor, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center.

Transcript

How does specialty drug coverage from commercial payers vary throughout the country?

At the Center for the Evaluation of Risk in Health at Tufts Medical Center, we’ve actually developed a database to address questions like that. The database includes 17 of the largest 20 commercial payers and includes thousands of specialty drug coverage decisions. In our paper published in Health Affairs last summer, we found that of hundreds of specialty drugs, only 16% were covered in the same way by the 17 commercial payers in our sample, meaning that 84% of those specialty drugs, coverage differed, meaning that one payer added restrictions to coverage while another payer did not. So, for instance, that could be that one payer added a step added to the coverage decision while another payer did not, or it could simply be that one payer added some kind of patient subgroup restriction, meaning that only patients who met certain clinical criteria could get access to the drug while other payers did not.

How does this variability impact patient outcomes?

I think this variability is very important and maybe most importantly, it does impact patients’ access. It means that a patient’s access differs depending on their insurance company. So, patients with similar clinical characteristics have differing access simply because they’re covered by different insurance companies. Also, I think importantly for patients who are switching between health plans, this could affect their access to a drug on which they’re currently stable on their initial health plan. I think it’s very important to quantify and really grasp that. The last thing would be for physicians and maybe other prescribing providers in that those providers will be tailoring their treatment decision not only to the patient’s clinical presentation or clinical characteristics but also to the patient’s insurance coverage, and therefore, this variation is very important to quantify and there’s a lot of work to be done to understand why this exists.

 
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up